Purchase these Two Healthcare Shares Instantaneously, Before Their Values Skyrocket Further
Getting into the nitty-gritty of the pharma world, we've got two standout players that are currently in the limelight. These companies have managed to surpass the usual steady revenue expectations common in the pharmaceutical sector, instead, they've been performing like growth stocks thanks to innovative drugs, blockbuster sales, and exciting growth prospects.
Let's dive into it!
1. Eli Lilly
Eli Lilly, known for its diverse treatment areas, has been shaking things up, especially in the weight loss department. With drugs like tirzepatide, marketed as Zepbound for weight loss and Mounjaro for type 2 diabetes, the company is raking in the big bucks, leading to double-digit revenue gains.
Both have reached blockbuster status, with Zepbound generating $1.2 billion and Mounjaro bringing in an impressive $3.1 billion in the latest quarter. Lilly is not stopping there, they're already working on other weight loss candidates in late-stage clinical trials, including an oral formulation that could revolutionize the injection-heavy industry.
Demand for these drugs has been skyrocketing, but Lilly has managed to keep up, recently announcing they'll produce 60% more doses in the first half of 2023 compared to the same period in 2022. And with the US obesity drug market forecasted to be between $100 billion to $130 billion by 2030, Eli Lilly, as a market leader today, is well-positioned to reap the benefits.
2. Vertex Pharmaceuticals
Vertex Pharmaceuticals, the global leader in cystic fibrosis treatment, is looking to expand its territory. After recently securing approval for Alyftrek, a drug that's even more effective and convenient than its top-seller Trikafta, produced in a once-daily format, Vertex is ready for a new era of growth.
CF drugs have already propelled Vertex's revenue into the billions, with product revenue soaring to over $2.7 billion in the latest quarter. But that's not all. Now, Vertex has applied to the FDA for the approval of suzetrigine, a potential game-changer for pain treatment.
If approved, suzetrigine could represent a major long-term catalyst for stock performance. Current pain management options are limited, often ineffective, and the prescription of opioids is discouraged due to addiction links. Vertex's non-opioid candidate could find significant market share, with the company studying the drug in additional pain indications. Vertex expects suzetrigine to become a "multibillion-dollar drug."
This innovation-focused biotech player has already climbed 87% over the past three years, but with these catalysts on the horizon, it looks like Vertex has plenty of room to grow even further.
- Investors looking to diversify their portfolio might consider investing in Eli Lilly's stocks due to its impressive financial performance and promising growth prospects in the weight loss market.
- The success of Vertex Pharmaceuticals in the cystic fibrosis treatment sector, evidenced by its blockbuster drugs and recent FDA approval, makes it an attractive option for those interested in finance and high-growth investment opportunities in the pharmaceutical industry.
